James S. Wilmott

69.7k citations

141 papers · 6.7k · 3 hit papers · h-index 38

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
Immunology top 1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer

Papers in

Oncology 95
- Cancer Immunotherapy and Biomarkers 48
- Cutaneous Melanoma Detection and Management 42
- CAR-T cell therapy research 27
- HER2/EGFR in Cancer Research 6
Molecular Biology 68
- Melanoma and MAPK Pathways 45
- Epigenetics and DNA Methylation 5

Co-authors: Richard A. Scolyer (132 shared papers)Georgina V. Long (92 shared papers)John F. Thompson (61 shared papers)Alexander M. Menzies (47 shared papers)Richard Kefford (20 shared papers)Peter Hersey (17 shared papers)Tuba N. Gide (21 shared papers)Hojabr Kakavand (15 shared papers)
Journals: Clinical Cancer Research (14 papers)Pathology (12 papers)Cancer Research (11 papers)Journal of Clinical Oncology (7 papers)Modern Pathology (6 papers)
Partner nations: Australia United States China

In The Last Decade

James S. Wilmott

132 papers receiving 6.7k citations

James S. Wilmott's Hit Papers

align trajectories log scale

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade 2019 · 446 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Clinical Cancer Research
2018 The Lancet Oncology
2011 Clinical Cancer Research

Peers

Countries citing papers authored by James S. Wilmott

Since Specialization

Citations

This map shows the geographic impact of James S. Wilmott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James S. Wilmott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James S. Wilmott more than expected).

Fields of papers citing papers by James S. Wilmott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James S. Wilmott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James S. Wilmott. The network helps show where James S. Wilmott may publish in the future.

Co-authors

The 25 scholars most cited alongside James S. Wilmott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James S. Wilmott Line = papers co-authored together James S. Wilmott links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 141 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study The Lancet Oncology ·Georgina V. Long, Victoria Atkinson, Serigne Lo, Shahneen Sandhu, Alexander Guminski, Michael P. Brown, James S. Wilmott, Jarem Edwards, Maria Gonzalez, Richard A. Scolyer, Alexander M. Menzies, Grant A. McArthur Hit paper breakdown →	2018	687
2	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma Clinical Cancer Research ·James S. Wilmott, Georgina V. Long, Julie R. Howle, Lauren E. Haydu, Raghwa Sharma, John F. Thompson, Richard Kefford, Peter Hersey, Richard A. Scolyer Hit paper breakdown →	2011	525
3	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade Clinical Cancer Research ·Imran G. House, Peter Savas, Junyun Lai, Amanda X. Y. Chen, Amanda J. Oliver, Zhi L. Teo, Kirsten L. Todd, Melissa A. Henderson, Lauren Giuffrida, Emma V. Petley, Kevin Sek, Sherly Mardiana, Tuba N. Gide, Camelia Quek, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Sherene Loi, Phillip K. Darcy, Paul A. Beavis Hit paper breakdown →	2019	446
4	PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials Pigment Cell & Melanoma Research ·Jason Madore, Ricardo E. Vilain, Alexander M. Menzies, Hojabr Kakavand, James S. Wilmott, Jessica Hyman, Jennifer H. Yearley, Richard Kefford, John F. Thompson, Georgina V. Long, Peter Hersey, Richard A. Scolyer	2014	340
5	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment Clinical Cancer Research ·Jarem Edwards, James S. Wilmott, Jason Madore, Tuba N. Gide, Camelia Quek, Annie Tasker, Angela L. Ferguson, Jinbiao Chen, Rehana Hewavisenti, Peter Hersey, Thomas Gebhardt, Wolfgang Weninger, Warwick J. Britton, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Georgina V. Long, Richard A. Scolyer, Umaimainthan Palendira	2018	332
6	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma Clinical Cancer Research ·Tuba N. Gide, James S. Wilmott, Richard A. Scolyer, Georgina V. Long	2017	328
7	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma The American Journal of Surgical Pathology ·Georgina V. Long, James S. Wilmott, David Capper, Matthias Preusser, Yuxiao E. Zhang, John F. Thompson, Richard Kefford, Andreas von Deimling, Richard A. Scolyer	2012	240
8	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma Clinical Cancer Research ·Ricardo E. Vilain, Alexander M. Menzies, James S. Wilmott, Hojabr Kakavand, Jason Madore, Alexander Guminski, Elizabeth Liniker, Benjamin Y. Kong, Adam Cooper, Julie R. Howle, Robyn P.M. Saw, Valerie Jakrot, Serigne Lo, John F. Thompson, Matteo S. Carlino, Richard Kefford, Georgina V. Long, Richard A. Scolyer	2017	199
9	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition Nature Communications ·Jenny Lee, Elena Shklovskaya, Su Yin Lim, Matteo S. Carlino, Alexander M. Menzies, Ashleigh Stewart, Bernadette Pedersen, Malama Irvine, Sara Alavi, Jean Yang, Dario Strbenac, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Richard A. Scolyer, Georgina V. Long, Richard Kefford, Helen Rizos	2020	198
10	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients Modern Pathology ·Hojabr Kakavand, Louise Jackett, Alexander M. Menzies, Tuba N. Gide, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Georgina V. Long, Richard A. Scolyer	2017	188
11	MicroRNA-149, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma Proceedings of the National Academy of Sciences* ·Lei Jin, Wang Hu, Chen Chen Jiang, (unknown), Chuan Chun Han, Ping Chu, (unknown), Rick F. Thorne, James S. Wilmott, Richard A. Scolyer, Peter Hersey, Xu Dong Zhang, Mian Wu	2011	157
12	BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma Journal of Investigative Dermatology ·Graham J. Mann, Gulietta M. Pupo, Anna Campain, Candace D. Carter, Sarah‐Jane Schramm, Svetlana Pianova, Sebastien K. Gerega, Chitra De Silva, Kenneth Lai, James S. Wilmott, Maria Synnott, Peter Hersey, Richard Kefford, John F. Thompson, (unknown), Richard A. Scolyer	2012	144
13	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients Clinical Cancer Research ·Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo E. Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard Kefford, Peter Hersey, Georgina V. Long, Richard A. Scolyer	2015	118
14	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma Clinical Cancer Research ·Jason Madore, Dario Strbenac, Ricardo E. Vilain, Alexander M. Menzies, Jean Yang, John F. Thompson, Georgina V. Long, Graham J. Mann, Richard A. Scolyer, James S. Wilmott	2016	92
15	Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis Human Molecular Genetics ·Diego M. Marzese, Richard A. Scolyer, Jamie L. Huynh, Sharon K. Huang, Hajime Hirose, Kelly K. Chong, Eiji Kiyohara, Jinhua Wang, Neal P. Kawas, Nicholas Donovan, Keisuke Hata, James S. Wilmott, Rajmohan Murali, Michael E. Buckland, Brindha Shivalingam, John F. Thompson, Donald L. Morton, Daniel F. Kelly, Dave S.�B. Hoon	2013	85
16	Epigenetic profiling for the molecular classification of metastatic brain tumors Nature Communications ·Javier I. J. Orozco, Theo Knijnenburg, Ayla O. Manughian-Peter, Matthew P. Salomon, Garni Barkhoudarian, John R. Jalas, James S. Wilmott, Parvinder Hothi, Xiaowen Wang, Yuki Takasumi, Michael E. Buckland, John F. Thompson, Georgina V. Long, Charles Cobbs, Ilya Shmulevich, Daniel F. Kelly, Richard A. Scolyer, Dave S.�B. Hoon, Diego M. Marzese	2018	84
17	Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling Oncotarget ·Anja Heinemann, Carleen Cullinane, Ricardo De Paoli‐Iseppi, James S. Wilmott, Dilini Gunatilake, Jason Madore, Dario Strbenac, Jean Yang, Kavitha Gowrishankar, Jessamy Tiffen, Rab K. Prinjha, Nicholas Smithers, Grant A. McArthur, Peter Hersey, Stuart Gallagher	2015	74
18	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases Modern Pathology ·Hojabr Kakavand, Ricardo E. Vilain, James S. Wilmott, Hazel Burke, Jennifer H. Yearley, John F. Thompson, Peter Hersey, Georgina V. Long, Richard A. Scolyer	2015	73
19	Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine Molecular Cancer Therapeutics ·James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard Kefford, Richard A. Scolyer, Georgina V. Long	2012	72
20	PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma Nature Communications ·Yan Ye, Lei Jin, James S. Wilmott, Wang Hu, Benafsha Yosufi, Rick F. Thorne, Tao Liu, Helen Rizos, Xu Guang Yan, Li Dong, Kwang Hong Tay, Hsin‐Yi Tseng, Su Guo, Charles E. de Bock, Chen Chen Jiang, Chunyan Wang, Mian Wu, (unknown), Peter Hersey, Richard A. Scolyer, Xu Dong Zhang	2013	70

About James S. Wilmott

James S. Wilmott is a scholar working on Oncology, Molecular Biology, Immunology, Cancer Research and Epidemiology, having authored 141 papers that have together received 6.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (48 papers), Melanoma and MAPK Pathways (45 papers), Cutaneous Melanoma Detection and Management (42 papers), Immunotherapy and Immune Responses (40 papers), CAR-T cell therapy research (27 papers), Cancer Genomics and Diagnostics (14 papers), HER2/EGFR in Cancer Research (6 papers) and Epigenetics and DNA Methylation (5 papers). The work is most often cited by research in Oncology (4.0k citations), Immunology (2.1k citations), Cancer Research (690 citations), Molecular Biology (2.7k citations) and Pulmonary and Respiratory Medicine (850 citations). James S. Wilmott has collaborated with scholars based in Australia, United States and China. Frequent co-authors include Richard A. Scolyer, Georgina V. Long, John F. Thompson, Alexander M. Menzies, Richard Kefford, Peter Hersey, Tuba N. Gide, Hojabr Kakavand, Lauren E. Haydu and Serigne Lo. Their work appears in journals such as Clinical Cancer Research, Pathology, Cancer Research, Journal of Clinical Oncology and Modern Pathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

James S. Wilmott

Impact in

Papers in i

In The Last Decade

James S. Wilmott

James S. Wilmott's Hit Papers

Peers

Countries citing papers authored by James S. Wilmott

Fields of papers citing papers by James S. Wilmott

All Works

About James S. Wilmott

Explore authors with similar magnitude of impact

Papers in